Zydus Lifesciences shares were trading at ₹1,169.65, down ₹17.35 or 1.46% despite announcing positive topline results from its completed EVIDENCES-X™ Phase II(b) clinical trial for Saroglitazar Magnesium. The stock touched an intraday high of ₹1,191.45 and low of ₹1,163, with trading volumes of 5,401 shares compared to its five-day average of 100,961 shares, representing a 94.65% decrease in volume. According to latest market data, the stock's muted reaction suggests investors may be taking a cautious approach to the positive trial results, perhaps awaiting further regulatory developments or additional clinical validation.
Zydus Lifesciences Limited announced successful completion of its EVIDENCES-X™ Phase II(b) clinical trial for Saroglitazar Magnesium, a promising treatment for Metabolic dysfunction Associated Steatohepatitis (MASH). The trial met its primary endpoint, showing resolution of steatohepatitis without worsening fibrosis at week 52 with a treatment difference of 26.5%. According to the latest reports, the prospective, multicentre, randomized, double-blind, placebo-controlled study enrolled 189 subjects who were randomized in a 1:1:1 ratio to receive Saroglitazar 2 mg, Saroglitazar 4 mg, or placebo over a 52-week treatment period. The study successfully met its primary endpoint, showing a 26.5% treatment difference in the resolution of steatohepatitis without worsening fibrosis at week 52. The trial also demonstrated encouraging findings across key secondary and exploratory endpoints, including improvements in liver histology parameters, steatosis, inflammation and ballooning assessments. Further details are expected to be presented at an upcoming Liver Congress.
The EVIDENCES-X trial achieved significant validation by enrolling subjects across multi-regional sites, including the US, Turkey, and Argentina, demonstrating efficacy across diverse cohorts. As reported by Business Upturn, the trial showed improvements in liver histology parameters, steatosis, inflammation and ballooning assessments. The study was led by co-Principal Investigators Prof. Naga Chalasani of Indiana University School of Medicine and Prof. Arun J. Sanyal of Virginia Commonwealth University. The positive outcome addresses the exact target regulators look for in complex liver diseases, with data from the EVIDENCES-X trial being presented at upcoming scientific meetings and submitted for publication in a peer-reviewed medical journal.
According to Business Upturn, Metabolic dysfunction Associated Steatohepatitis (MASH) and Metabolic dysfunction Associated Steatohepatitis (MASLD) continue to represent significant unmet medical needs globally. MASH remains a significant global health burden with approximately 5% to 20% of the adult population affected. MASH is characterized by hepatic steatosis, inflammation, and hepatocellular injury and can progress to advanced fibrosis, cirrhosis, liver failure, liver cancer, and death. The successful conclusion of this global Phase II(b) trial represents a major clinical victory for Zydus Lifesciences, with the positive results building upon previously published findings from earlier Phase II studies of Saroglitazar in MASH and MASLD patients.
Saroglitazar Mg was approved by the Drug Controller General of India (DCGI) for the treatment of MASH and MASLD in India in 2020, while Saroglitazar Mg is an investigational compound in the United States and has not yet been approved by the U.S. Food & Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of MASH and MASLD. The positive EVIDENCES-X trial results strengthen Zydus's global clinical roadmap, with the company targeting US FDA PDUFA action date on November 27, 2026 for Saroglitazar in treating Primary Biliary Cholangitis (PBC). The successful advancement of this proprietary NCE (New Chemical Entity) pipeline reduces the company's reliance on low-margin generic market, improving its long-term margin profile. Investors should monitor the upcoming US FDA PDUFA action date as the next key catalyst for the company's global liver franchise.
Commenting on the positive outcome, Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, stated, "The successful completion of the EVIDENCES-X™ Phase II(b) trial and achievement of the primary endpoint marks an important milestone in our MASH development programme. These results reinforce the therapeutic potential of Saroglitazar Mg and our commitment to developing innovative treatment options for patients suffering from chronic liver diseases." Zydus reported strong financial performance with consolidated revenue growing 22% YoY to ₹8,020 crore in Q1 FY27, with net profit of ₹940 crore. On June 16, 2026, the company completed the acquisition of US-based oncology drug manufacturer Assertio Holdings for $166 million. Additionally, on July 3, 2026, Zydus signed an MoU with Apollo Hospitals to expand the Shield Multi-Cancer Detection test in India. The positive EVIDENCES-X trial results validate Zydus's key asset Saroglitazar Mg and enhance its positioning for global out-licensing and regulatory partnerships.
